Nilda Mesa Sells 228 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 228 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $505.87, for a total transaction of $115,338.36. Following the completion of the transaction, the director owned 5,580 shares in the company, valued at approximately $2,822,754.60. This trade represents a 3.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

United Therapeutics Stock Down 0.4%

Shares of UTHR stock opened at $498.48 on Thursday. The firm has a 50 day moving average price of $517.63 and a two-hundred day moving average price of $540.68. The company has a market capitalization of $21.38 billion, a PE ratio of 17.83, a price-to-earnings-growth ratio of 2.51 and a beta of 0.56. United Therapeutics Corporation has a 12-month low of $397.97 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.41 earnings per share. As a group, research analysts expect that United Therapeutics Corporation will post 26.21 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on UTHR shares. Royal Bank Of Canada lowered their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $646.00.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Talon Private Wealth LLC grew its holdings in shares of United Therapeutics by 31.8% during the 2nd quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company’s stock worth $3,659,000 after purchasing an additional 1,630 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in shares of United Therapeutics by 4.4% in the second quarter. Sequoia Financial Advisors LLC now owns 2,530 shares of the biotechnology company’s stock worth $1,371,000 after purchasing an additional 106 shares during the period. Tidal Investments LLC raised its stake in United Therapeutics by 1.6% in the second quarter. Tidal Investments LLC now owns 34,012 shares of the biotechnology company’s stock valued at $18,429,000 after purchasing an additional 547 shares in the last quarter. Archford Capital Strategies LLC acquired a new position in United Therapeutics in the second quarter valued at about $552,000. Finally, Engineers Gate Manager LP bought a new stake in United Therapeutics during the second quarter worth about $2,524,000. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.